Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.
Melissa Raven is a psychiatric epidemiologist and policy analyst. She is qualified as a clinical psychologist, but has worked primarily as a lecturer and researcher in public health and primary health care. She has extensive experience teaching research methods and critical analysis, primarily at a postgraduate level.
Melissa's main interests are misuse of psychiatric epidemiology, inappropriate psychiatric diagnosis, inappropriate prescribing of psychotropic drugs, and promotional strategies used by pharmaceutical companies, key opinion leaders, opportunistic policy makers, and other players with vested interests. She was a founding member of Healthy Skepticism.
Year Citation 2016 Le Noury, J., Nardo, J., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2016). Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. International Journal of Risk and Safety in Medicine, 28(3), 143-161.
DOI Scopus3 Europe PMC1
2016 Raven, M. (2016). Health of grey nomads: On the move and under the health sector radar. AUSTRALIAN JOURNAL OF RURAL HEALTH, 24(3), 182-187.
DOI WoS3 Europe PMC2
2015 Raven, M. (2015). Analysis of Mortality in Mental Disorders. JAMA Psychiatry, 72(11), 1150.
2015 Le Noury, J., Nardo, J., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2015). Authors' reply to Sasich and Linden. BMJ: British Medical Journal, 351(351), h5412.
2015 Le Noury, J., Nardo, J., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2015). Restoring study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351, h4320-1-h4320-16.
DOI Scopus139 WoS108 Europe PMC65
2013 Raven, M., Jureidini, J., & Stuart, G. (2013). Transparency and accountability in early psychosis intervention research. Australian and New Zealand Journal of Psychiatry, 47(7), 680-681.
DOI Scopus1 WoS2 Europe PMC1
2013 Raven, M. (2013). EPPIC mirage: Cost-effectiveness of early psychosis intervention. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 47(7), 599-601.
DOI WoS5 Europe PMC6
2013 Frances, A., & Raven, M. (2013). Two views on the DSM-5: the need for caution in diagnosing and treating mental disorders.. American family physician, 88(8), Online. 2013 Raven, M., Butler, C., & Bywood, P. (2013). Video-based telehealth in Australian primary health care: current use and future potential. AUSTRALIAN JOURNAL OF PRIMARY HEALTH, 19(4), 283-286.
DOI WoS9 Europe PMC9
2012 Raven, M., & Parry, P. (2012). Psychotropic marketing practices and problems: implications for DSM-5. Journal of Nervous and Mental Disease, 200(6), 512-516.
DOI WoS7 Europe PMC2
2012 Raven, M. (2012). Targeted primary care-based mental health services for young Australians.. The Medical journal of Australia, 196(10), 627.
2012 Rogers, W., Zutlevics, T., Raven, M., & Jureidini, J. (2012). Guidance offers little in the way of ethics or transparency. BRITISH MEDICAL JOURNAL, 344(feb21 1), 1 page.
2012 Jureidini, J., & Raven, M. (2012). Healthy Kids Check: Lack of transparency and misplaced faith in the benefits of screening. Australian & New Zealand Journal of Psychiatry, 46(10), 924-927.
DOI Scopus6 WoS6 Europe PMC4
2012 Raven, M., Stuart, G., & Jureidini, J. (2012). 'Prodromal' diagnosis of psychosis: ethical problems in research and clinical practice. Australian and New Zealand Journal of Psychiatry, 46(1), 64-65.
DOI Scopus8 WoS6 Europe PMC6
2012 Jureidini, J., & Raven, M. (2012). Novel melatonin-based treatments for major depression. Lancet, 379(9812), 216-217.
DOI Scopus2 WoS11 Europe PMC7
2011 Raven, M. (2011). Omission of evidence about 5-year outcomes. BRITISH JOURNAL OF PSYCHIATRY, 198(3), 239-240.
2010 Isacsson, G., Rich, C., Jureidini, J., & Raven, M. (2010). The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. British Journal of Psychiatry, 196(6), 429-433.
DOI Scopus39 WoS37 Europe PMC23
2008 Jureidini, J., Mintzes, B., & Raven, M. (2008). Does direct-to-consumer advertising of antidepressants lead to a net social benefit?. Pharmacoeconomics, 26(7), 557-566.
DOI WoS4 Europe PMC4
2006 Raven, M. K. (2006). Depression should be managed like a chronic disease: myth of 15% suicide rate was promulgated again.. BMJ (Clinical research ed.), 332(7550), 1154.
DOI Europe PMC1
2005 Mansfield, P., Raven, M., & Jureidini, J. (2005). Depressed youth, suicidality and antidepressants. MEDICAL JOURNAL OF AUSTRALIA, 183(5), 275.
WoS1 Europe PMC1
2005 Raven, M. K. (2005). Do selective serotonin reuptake inhibitors cause suicide? Suicide rate of 15% in editorial is misleading.. BMJ (Clinical research ed.), 330(7500), 1150.
2005 Raven, M., Rogers, W., & Jureidini, J. (2005). Partnerships between academic psychiatry and the pharmaceutical industry. Australasian Psychiatry, 13(1), 83-84.
Year Citation 1998 Shoobridge, J. A., Raven, M., Addy, D., Allsop, S., & Kamienecki, G. (1998). Gambling and SelfHelp. Adelaide: Department of Human Services.
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2018 Co-Supervisor Patterns, Predictors and Outcomes of Prescribed Psychotropic Drug Use in Australian Children and Adolescents Doctor of Philosophy Doctorate Full Time Ms Julie Marie Klau 2018 Co-Supervisor Towards a New Paradigm for the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD) Doctor of Philosophy Doctorate Part Time Mrs Sheelah Margaret Mills
Connect With Me